- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05407324
Dazucorilant en pacientes con esclerosis lateral amiotrófica (DAZALS) (DAZALS)
Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo que evalúa la seguridad y la eficacia de CORT113176 (dazucorilant) en pacientes con esclerosis lateral amiotrófica (DAZALS)
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
In Part 1, eligible ALS patients will be randomized to one of three treatment arms (1:1:1) across North America and Europe for a 24-week double-blind treatment period. Patients who complete participation (i.e., complete all visits) in the double-blind treatment period will be eligible for participation in a 132-week open-label extension (OLE) study. A daily dose of 300 mg dazucorilant will be used in the OLE period. Patients who complete the double-blind treatment period and who do not enter the OLE will enter the 132-week follow-up period.
In Part 2, eligible ALS patients will receive open-label treatment to evaluate dose titration and tolerability of dazucorilant. The dose titration will begin with an initial 75 mg once daily dose, and the dose will be titrated up as tolerated in 75 mg increments until the 300 mg once daily target dose is reached and maintained for 3 weeks. Patients who complete participation in the dose-titration treatment period will be eligible to continue treatment with dazucorilant 300 mg once daily in a 52-week open-label extension portion of the study.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 13353
- 255
-
Bonn, Alemania, 53127
- 270
-
Dresden, Alemania, 1307
- 268
-
Hanover, Alemania, 30625
- 260
-
Jena, Alemania, 7747
- 265
-
München, Alemania, 81675
- 386
-
Rostock, Alemania, 18147
- 267
-
Ulm, Alemania, 89081
- 269
-
-
-
-
-
Leuven, Bélgica, 3000
- 108
-
-
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 3Z5
- 425
-
-
Quebec
-
Montreal, Quebec, Canadá, H3A2B4
- 273
-
-
-
-
-
Barcelona, España, 08003
- 302
-
Barcelona, España, 08035
- 115
-
Madrid, España, 28046
- 303
-
Málaga, España, 29010
- 282
-
Valencia, España, 46026
- 194
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85013
- 062
-
-
California
-
San Francisco, California, Estados Unidos, 94109
- 278
-
-
New Jersey
-
Neptune City, New Jersey, Estados Unidos, 07753
- 287
-
-
New York
-
New York, New York, Estados Unidos, 10032
- 353
-
-
-
-
-
Bron, Francia, 69500
- 422
-
Lille, Francia, 59037
- 258
-
Limoges, Francia, 87042
- 257
-
Marseille, Francia, 13385
- 261
-
Montpellier, Francia, 42395
- 423
-
Nice, Francia, 06001
- 259
-
Paris, Francia, 75651
- 262
-
Tours, Francia, 37000
- 256
-
-
-
-
-
Dublin, Irlanda, D09 YD60
- 253
-
-
-
-
-
Utrecht, Países Bajos, 3584 CW
- 264
-
-
-
-
-
Bydgoszcz, Polonia, 85-163
- 283
-
Krakow, Polonia, 30721
- 385
-
Warsaw, Polonia, 01-684
- 254
-
Warsaw, Polonia, 02-473
- 274
-
-
-
-
-
Stoke-on-Trent, Reino Unido, ST4 6QG
- 263
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male and female patients ≥18 years of age with sporadic or familial ALS. In Part 1, patients must have a risk of ALS progression characterized by a European Network for the Cure of ALS (ENCALS) risk profile score ≥ -6 and ≤ -3. In Part 2 patients must have a risk of ALS progression characterized by an Treatment Research Initiative to Cure ALS (TRICALS) risk profile score ≥ -7 and ≤ -3.
- If taking riluzole, edaravone, and/or sodium phenylbutyrate and taurursodiol, must be on a stable dose prior to Screening. Sodium phenylbutyrate and taurursodiol are not permitted for patients enrolled in Part 2 of the study.
- Part 2 only: Patients with a pathogenic mutation in superoxide dismutase 1 gene (SOD1) must not be receiving treatment with tofersen or eligible for treatment with tofersen if available. Patients who have received prior treatment with tofersen and discontinued due to safety and/or efficacy reasons prior to Screening are eligible.
- Part 2 only: Use of ultra high-dose methylcobalamin for the treatment of ALS is permitted provided the patient has been on a stable dose for ≥11 weeks prior to the Day 1 visit.
Exclusion Criteria:
- History of a clinically significant non-ALS neurologic disorder
- Inability to swallow capsules.
- Blood platelet count <150,000/mm^3.
- Renal impairment indicated by Estimated Glomerular Filtration Rate (eGFR) ≤30 mL/min/1.73 m^2. Part 2 only: Patients with a recent history of acute kidney injury should have returned to their baseline renal function (i.e, eGFR prior to acute kidney injury) prior to enrollment.
- Human immunodeficiency virus (HIV) or current chronic/active infection with hepatitis C virus or hepatitis B virus. Part 2 only: Known history of HIV or chronic/active infection with hepatitis C or hepatitis B virus; testing does not need to be performed if infection status is unknown.
- Women who are pregnant, planning to become pregnant, or are breastfeeding.
- Use of non-invasive ventilation (NIV) or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation.
- Cancer that is currently being treated (except adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin, stage I endometrial cancer or carcinoma in situ of the cervix or breast) or a history of cancer with an expected survival < 2 years.
- Current or anticipated need of a diaphragm pacing system (DPS).
- Previous exposure or treatment with glucocorticoid receptor modulators or antagonists.
- Taking, or have taken, any systemic, inhaled, or potent dermatologic topical corticosteroids (Class I to III) within a period equivalent to 5 half-lives of the corticosteroid used prior to first dose of study drug. Patients who have stopped glucocorticoid use should have an alternative option if their condition deteriorates during the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1: CORT113176 (Dazucorilant) 300 mg
300 mg of dazucorilant will be administered once daily. |
300 mg of dazucorilant will be administered once daily in 4 capsules of 75 mg dazucorilant/capsule.
Otros nombres:
|
|
Experimental: Part 1: CORT113176 (Dazucorilant) 150 mg
150 mg of dazucorilant will be administered once daily. |
Dazucorilant and placebo will be administered once daily in 4 capsules, 2 capsules with 75 mg dazucorilant/capsule, and 2 capsules of placebo equivalent.
Otros nombres:
Placebo will be administered once daily in capsules of placebo equivalent. |
|
Comparador de placebos: Part 1: Placebo (matched to study drug)
Placebo will be administered once daily. |
Placebo will be administered once daily in capsules of placebo equivalent. |
|
Experimental: Part 2: CORT113176 (Dazucorilant) 75 - 300 mg Dose-titration
75 mg of dazucorilant will be administered once daily for 1 week, and increased weekly in 75 mg increments up to 300 mg once daily. |
Dazucorilant will be administered once daily in 75-mg capsules.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.
Periodo de tiempo: Baseline to Week 24
|
This outcome measure is assessed in study Part 1. |
Baseline to Week 24
|
|
Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs
Periodo de tiempo: Baseline to Week 24
|
This outcome measure is assessed in study Part 1. |
Baseline to Week 24
|
|
Incidence of treatment-emergent AEs and SAEs
Periodo de tiempo: Baseline up to Week 12
|
This outcome measure is assessed in study Part 2. |
Baseline up to Week 12
|
|
Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug
Periodo de tiempo: Baseline up to Week 12
|
This outcome measure is assessed in study Part 2. |
Baseline up to Week 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline to Week 24 in muscle strength (assessed using hand-held dynamometer)
Periodo de tiempo: Baseline to Week 24
|
This outcome measure is assessed in study Part 1. |
Baseline to Week 24
|
|
Change from Baseline to Week 24 in Percent Slow Vital Capacity
Periodo de tiempo: Baseline to Week 24
|
This outcome measure is assessed in study Part 1. |
Baseline to Week 24
|
|
Change from Baseline to Week 24 in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
Periodo de tiempo: Baseline to Week 24
|
This outcome measure is assessed in study Part 1. |
Baseline to Week 24
|
|
Time to Death
Periodo de tiempo: From randomization date to the date of death from any cause up to 156 weeks
|
This outcome measure is assessed in study Part 1. |
From randomization date to the date of death from any cause up to 156 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Sophia Majeed, PharmD, PhD, Corcept Therapeutics Incorporated
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Neuromusculares
- Enfermedades metabólicas
- Enfermedades neurodegenerativas
- Enfermedades de la médula espinal
- Proteinopatías TDP-43
- Deficiencias de proteostasis
- Enfermedad de la neuronas motoras
- Enfermedades Nutricionales y Metabólicas
- La esclerosis lateral amiotrófica
- CORT113176
Otros números de identificación del estudio
- CORT113176-652
- 2021-005611-31 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .